Perceptive Advisors’s Marker Therapeutics MRKR Stock Holding History

Perceptive Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-200,000	Closed	-$10.2M	–	121
2019 Q3	$10.2M	Hold	200,000	–	–	0.28%	56
2019 Q2	$15.8M	Hold	200,000	–	–	0.36%	53
2019 Q1	$13.2M	Hold	200,000	–	–	0.37%	53
2018 Q4	$11.1M	Buy	+200,000	New	+$14.6M	0.42%	48

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Perceptive Advisors's MRKR Position: Q4 2019 in Review

Perceptive Advisors sold out of Marker Therapeutics (MRKR) in Q4 2019, closing a stake of 200,000 shares — an estimated $10.2M sold.

Perceptive Advisors first reported a position in MRKR in Q4 2018 and held it in 4 quarters. The position peaked at $15.8M in Q2 2019. 65 funds tracked by Wall St. Rank hold MRKR as of Q4 2019.

Perceptive Advisors reported no remaining Marker Therapeutics position as of Q4 2019 after selling out during the quarter.
Perceptive Advisors sold 200,000 Marker Therapeutics shares in Q4 2019, an estimated $10.2M.
Perceptive Advisors first reported a position in Marker Therapeutics in Q4 2018 and held it in 4 quarters.
Perceptive Advisors's Marker Therapeutics position peaked at $15.8M in Q2 2019.
65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2019.

Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.